MX9703653A - Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria. - Google Patents

Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria.

Info

Publication number
MX9703653A
MX9703653A MX9703653A MX9703653A MX9703653A MX 9703653 A MX9703653 A MX 9703653A MX 9703653 A MX9703653 A MX 9703653A MX 9703653 A MX9703653 A MX 9703653A MX 9703653 A MX9703653 A MX 9703653A
Authority
MX
Mexico
Prior art keywords
inflammatory response
composition
diseases caused
treating mammalian
mammalian diseases
Prior art date
Application number
MX9703653A
Other languages
English (en)
Inventor
Stanley E Katz
Original Assignee
Cellular Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences Inc filed Critical Cellular Sciences Inc
Publication of MX9703653A publication Critical patent/MX9703653A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para tratar el estado de enfermedad en mamíferas ocasionado por células mamíferas involucradas en la respuesta inflamatoria se presenta. Las células mamíferas que participan en la respuesta inflamatoria se ponen en contacto con un mediador de la respuesta inflamatoria que reduce la respuesta inflamatoria indeseable y en un antioxidante. El mediador de la respuesta inflamatoria puede además proporcionar una fuente de energía celular y ser un bloque constructivo en la síntesis celular de otros componentes celulares. También se presentan composiciones para reducir y tratar la respuesta inflamatoria indeseable.
MX9703653A 1995-09-19 1996-09-06 Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria. MX9703653A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US396295P 1995-09-19 1995-09-19
PCT/US1996/014304 WO1997010818A1 (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response

Publications (1)

Publication Number Publication Date
MX9703653A true MX9703653A (es) 1998-07-31

Family

ID=21708422

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9703653A MX9703653A (es) 1995-09-19 1996-09-06 Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria.

Country Status (10)

Country Link
EP (1) EP0804181A4 (es)
JP (1) JP4459303B2 (es)
AU (1) AU719332B2 (es)
CA (1) CA2205112C (es)
IL (1) IL119225A (es)
MX (1) MX9703653A (es)
NZ (1) NZ306832A (es)
TW (1) TW434012B (es)
WO (1) WO1997010818A1 (es)
ZA (1) ZA967833B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146391A0 (en) * 1999-05-14 2002-07-25 Cellular Sciences Inc Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
AU2002255805B2 (en) * 2001-03-15 2005-03-24 North Shore Long Island Jewish Research Institute Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
US20030105162A1 (en) * 2001-08-21 2003-06-05 Celluar Sciences, Inc. Method for treating bronchial constriction and bronchospasm
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US6623723B2 (en) * 2001-08-21 2003-09-23 Cellular Sciences Inc. Method for treating bronchial constriction and bronchospasm
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
JP5630750B2 (ja) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
US11771739B2 (en) 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
EP3797766A1 (en) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions for use in reducing inflammation
CN114641562B (zh) * 2019-11-14 2025-07-08 默克专利股份公司 细胞培养基

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1857M (fr) * 1962-03-08 1963-06-10 Roussel Uclaf Nouveau médicament notamment pour le traitement des maladies d'origine virale.
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4158057A (en) * 1975-03-28 1979-06-12 Stanko Ronald T Prevention of the accumulation of fatty deposits in the liver
US4021572A (en) * 1975-07-23 1977-05-03 Scott Eugene J Van Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
US4521375A (en) * 1982-11-23 1985-06-04 Coopervision, Inc. Sterilizing treatment with hydrogen peroxide and neutralization of residual amounts thereof
DE3302694A1 (de) * 1983-01-27 1984-08-02 Retheto Filmtechnik Theilemann & Co, 8000 München Mundpflegemittel
AU4634685A (en) * 1984-06-22 1986-01-24 R.L. Veech Electrolyte solutions and in vivo use thereof
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
JPS63135370A (ja) * 1986-11-26 1988-06-07 Grelan Pharmaceut Co Ltd 抗アレルギ−剤
IN168530B (es) * 1987-11-06 1991-04-20 Lyphomed Inc
WO1990000900A1 (en) * 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
JP2794021B2 (ja) * 1988-11-02 1998-09-03 エーザイ株式会社 アゼラスチン或いはその塩類含有経皮適用製剤
AU7699191A (en) * 1990-03-30 1991-10-30 Amgen, Inc. Respiratory burst suppression factor
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
CA2129732A1 (en) * 1992-02-25 1993-09-02 Alain Martin Cytoprotective compositions containing pyruvate and antioxidants
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
JP3236658B2 (ja) * 1992-04-27 2001-12-10 花王株式会社 気管支拡張剤
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof

Also Published As

Publication number Publication date
EP0804181A4 (en) 2005-02-02
EP0804181A1 (en) 1997-11-05
CA2205112C (en) 2008-11-18
JPH10509463A (ja) 1998-09-14
AU6915996A (en) 1997-04-09
TW434012B (en) 2001-05-16
NZ306832A (en) 2001-04-27
CA2205112A1 (en) 1997-03-27
IL119225A (en) 2000-09-28
IL119225A0 (en) 1996-12-05
AU719332B2 (en) 2000-05-04
JP4459303B2 (ja) 2010-04-28
WO1997010818A1 (en) 1997-03-27
ZA967833B (en) 1997-06-02

Similar Documents

Publication Publication Date Title
MX9703653A (es) Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria.
PL323737A1 (en) Method of controlling sialination of proteins produced by cultures of mammals tissue cells
AU4295496A (en) Production of a contractile smooth muscle
BR9910864A (pt) Compostos anti-inflamatórios para inibição de aderência celular
CA2374003A1 (en) Improved cellular uptake of bioactive agents
AU2542697A (en) Methods and compositions for cellular and metabolic engineering
WO2000031237A3 (en) Method of cloning porcine animals
TR199900262T2 (xx) Drospirenon (6�, 7�; 15�, 16�-dimetilen-3-okso-17 alfa-pregn-4-ene-21, 17-karbolakton, DRSP) ve y�ntemin ara �r�nleri olarak 7alfa-(3-hidroksi-1-propil)-6�, 7�;15�, 16�-dimetilen-5�-androstan-3�, 5, 17B-triol (ZK92836) ve 6�, 7�;15�, 16�-dimetilen - 5� -hidroksi-3-okso-17alfa-androstan-21,17-karbolaktonun (90965) �retilmeleri i�in y�ntem.
TR199801361T2 (xx) Yeni ikameli imidazol bile�imleri.
BR0112160A (pt) Agentes antiinflamatórios seletivos para glicocorticóides
DK0799058T3 (da) Forbedringer af eller med hensyn til endometriefunktion
EA200100103A1 (ru) Ингибиторы адгезии клеток
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
AU1116400A (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
NO975557L (no) Immortalisering og dissimortalisering av celler
DE59706780D1 (de) Verfahren zur herstellung von solvens-stabilisierten metallkolloiden und trägerfixierten metallclustern
MXPA02011858A (es) Inhibidores de adhesion de celula mediada por alfabeta2.
ATE377022T1 (de) Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
NZ330244A (en) Isoxazole derivatives useful in the treatment of inflammatory diseases
NO20000576L (no) Blanding og fremgangsmåte for regulering av celleproliferasjon og celledød
IL146391A0 (en) Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
DK1000154T3 (da) Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
AU4853997A (en) Immortalized human corneal epithelial cell line
AU2003288621A1 (en) Rna bioassay
IT1173489B (it) Procedimento di preparazione di 1-metil-10alfa-metossilumilisergolo e di suci esteri,e intermedi per la loro preparazione